Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Peptides for Beginners: What to Know

What peptides are, why they took off, which ones FDA has approved, how people take them, and what studies and community reports say, side by side.

Peptide Schedule Research TeamReviewed Oct 31, 2026

14 min read

In short

Peptides are short chains of amino acids, the building blocks of proteins. Many carry signals between cells. Some are FDA-approved drugs, like semaglutide for weight management (STEP 1 trial). Most of the 150 on this site have no FDA-approved product. Their human evidence runs from none at all to large trials.

Which peptides have been tested in people?

45 of the 104 peptides here without an FDA-approved product have no published human studies.

See the numbers
Evidence tiers of the 104 peptides with no FDA-approved product
TierCount% of 104What it meansExample
Approved outside the US1615%A regulator outside the US has approved a medicine made from it.Semax
Phase 3 trial1010%A phase 3 trial in people has finished, or its results are published.Retatrutide
Phase 2 trial1413%The furthest finished or published human research is a phase 2 trial.BPC-157
Phase 1 trial66%The furthest finished or published human research is a phase 1 safety trial.GHRP-6
Small human studies only1313%People have taken it in published studies, but none is a finished phase 1 to 3 trial. These are pilots, case reports or small unphased studies.GHK-Cu
No human studies found4543%No finished or published study in people was found. The research is in animals, cells or test tubes.TB-500
Covers every peptide on this site with no FDA-approved product. From the Peptide Evidence Gap study (ClinicalTrials.gov and PubMed), checked Oct 8 and corrected Oct 28, 2026.

What are peptides?

Peptides are short chains of amino acids, the building blocks of proteins, typically 2-50 amino acids long. Many of them carry signals between cells. Your body makes its own, such as oxytocin and glucagon, and both are also FDA-approved drugs.

Where a peptide ends and a protein begins depends on who's counting. Under FDA's rule, a chain of more than 40 amino acids counts as a protein (21 CFR 600.3 (opens in a new tab)).

Peptides are a big drug class, too. About 130 peptides are on the market, by one 2026 count (PMID 41683395). Counts differ because definitions differ. This site profiles 150 peptides and related compounds. Of those, 35 hold a current US approval, all listed on the FDA-approved peptides page.

Most of the others have no US approval, and their human evidence runs from large trials to none at all. Terms like receptor, agonist and half-life are defined in the peptide glossary.

Open the peptide calculator

How do peptides work in the body?

Most peptides work by binding receptors, the proteins on the surface of a cell. Each peptide fits certain receptors, like a key in a lock, and switches a signal on or off. That signal changes what the cell does next.

Semaglutide is the best-known example. It's a GLP-1 receptor agonist, built on a gut hormone that slows stomach emptying and turns down appetite. In the STEP 1 trial of 1,961 adults, those on semaglutide lost 14.9% of body weight at 68 weeks, against 2.4% on placebo (PMID 33567185).

Newer drugs hit more receptors at once. Tirzepatide adds the GIP receptor (SURMOUNT-1, PMID 35658024). Retatrutide adds the glucagon receptor as well, which makes it a triple agonist (PMID 37366315).

For most research peptides, what's known about the mechanism comes from animals. A 2025 review of BPC-157 found 36 studies, and 35 of them were preclinical (PMID 40756949).

How does a peptide send a signal?

A peptide fits a receptor on a cell like a key; semaglutide, for example, fits the GLP-1 receptor.

A peptide drawn as a chain of eight beads, each bead one amino acid, above a size line: 2 to 50 amino acids is a peptide; FDA counts a chain of more than 40 as a protein.each bead = one amino acidPeptide: 2-50 amino acids24050Over 40: FDA counts it as a protein
A short peptide chain docks into a receptor on the cell membrane, and a signal ring appears inside the cell.outside the cellinside the cellreceptorpeptidesignal
The chain: a peptide is a short chain of amino acids, 2 to 50 of them; FDA counts a chain of more than 40 as a protein (21 CFR 600.3 (opens in a new tab)). The receptor: the peptide docks into its receptor on the cell surface, and the cell passes the signal inside.

Why are peptides so popular right now?

Five forces drove the boom: GLP-1 drugs, drug shortages, retatrutide's trial results, new rules for research peptides and a huge online conversation. US searches for "peptides" grew about 37-fold in under eight years. Google Ads data put them at 33,100 a month in October 2018 and 1,220,000 at the 2026 peak (Google Ads via DataForSEO, US). Google counts "peptide" and "peptides" as one term.

On a shared US scale, "peptides" overtook "ozempic" in March 2026, 69 to 53. That hadn't happened since spring 2021, when both scored under 10. Interest peaked in April 2026 at 82, where Ozempic's all-time high in May 2024 sets 100 (Google Trends (opens in a new tab)).

GLP-1 drugs went first. Semaglutide and tirzepatide are peptides, and they made the word familiar. In late 2025, 12% of US adults said they currently take a GLP-1 drug (KFF, Nov 2025 (opens in a new tab)). In spring 2024 it was 6% (KFF, May 2024 (opens in a new tab)). Lilly's tirzepatide sales grew from $0.48 billion in 2022 to $36.5 billion in 2025 (Lilly 10-K, 2025 (opens in a new tab); 2023 (opens in a new tab)). The semaglutide vs tirzepatide page compares the two.

Shortages opened the door to compounding. FDA listed Wegovy, Ozempic and tirzepatide as in shortage in 2022, so pharmacies could compound copies. FDA declared those shortages over in 2024 and 2025. Still, 18% of current GLP-1 weight-loss users take a compounded or custom-mixed version (Gallup, 2026 (opens in a new tab)).

Retatrutide raised the ceiling. Retatrutide went from a phase 2 paper in 2023 (PMID 37366315) to phase 3 results in 2025 and 2026, led by TRIUMPH-1 (PMID 42814954).

The rules on research peptides moved. In April 2026, 12 peptides left FDA's Category 2 list. In July, an FDA advisory committee backed six of them for compounding. Both steps coincided with the search peak; the regulatory tracker logs each one with its date.

The conversation got huge. A 2026 study read 410,198 Reddit posts about semaglutide or tirzepatide, and 67,008 posters said they took one (Sehgal, Nature Health 2026 (opens in a new tab)). On YouTube, the most-viewed peptide explainer passed 19 million views in under two months. A 2024 Huberman Lab episode on peptide therapeutics passed 1.2 million (view counts read Oct 31, 2026).

How fast did Americans start searching for peptides?

US Google interest in “peptides” rose from 2 in January 2015 to 82 in April 2026, and in March 2026 it overtook “ozempic” for the first time since 2021.

33,100 → 1,220,000US searches a month for “peptides” (Oct 2018 → Mar 2026 peak, Google Ads)

Relative interest (Ozempic’s May 2024 peak = 100)

050100201520172019202120232025123589
  • peptides
  • ozempic
  • retatrutide
See the numbers
Google Trends, US, relative interest (Ozempic's May 2024 peak = 100)
Monthpeptidesozempicretatrutide
Jan 20152––
Jan 20162––
Jan 20172––
Jan 201840–
Jan 201952–
Jan 202073–
Jan 202184–
Jan 202288–
Jan 202310480
Jan 202412650
May 2024111000
Jan 202515622
Jan 2026454918
Mar 2026695324
Apr 2026825124
Jun 2026764528
Sep 2026473318

– = no data. October 2026 is a partial month and is left out of the chart. "bpc 157" is on the same request but peaks at 7 on this scale, so it is not drawn.

US Google searches a month for "peptides" (Google Ads)
MonthSearches
Oct 201833,100
Jan 202160,500
Jan 2023110,000
Oct 2024135,000
Jan 2025165,000
Oct 2025368,000
Jan 2026823,000
Mar 20261,220,000
Sep 2026823,000
Google Trends, US, web search, one shared 0-100 scale, retrieved Oct 31, 2026 (opens in a new tab). Search counts: Google Ads via DataForSEO, US. Numbered pins match the list below.

What drove the peptide boom?

GLP-1 drugs made peptides mainstream: 12% of US adults were taking one in late 2025, double the share in spring 2024.

  • 12%

    of US adults take a GLP-1

    KFF, Nov 2025; 6% in May 2024

  • $36.5B

    Tirzepatide sales in 2025, up from $0.48B in 2022

    Lilly 10-K

  • 18%

    of GLP-1 weight-loss users take a compounded or custom-mixed version

    Gallup, 2026

  1. Ozempic (semaglutide) approved for type 2 diabetesDrugs@FDA NDA 209637 (opens in a new tab)
  2. Wegovy (semaglutide) approved for weight managementDrugs@FDA NDA 215256 (opens in a new tab)
  3. Shortages: Wegovy (Mar 31), Ozempic (Aug 23) and tirzepatide (Dec 15) listed, so pharmacies could compound copiesFDA order, semaglutide (opens in a new tab) · FDA memo, tirzepatide (opens in a new tab)
  4. Retatrutide phase 2: 24.2% average weight loss at 48 weeks on the top dose vs 2.1% on placeboPMID 37366315 (opens in a new tab)
  5. FDA says the tirzepatide and semaglutide shortages are over; compounding grace periods end Feb-May 2025FDA memo, tirzepatide (opens in a new tab) · FDA order, semaglutide (opens in a new tab)
  6. 12 peptides, BPC-157 and TB-500 among them, leave FDA Category 2 (effective Apr 22)FDA 503A categories list (opens in a new tab) · What the removal means
  7. Retatrutide TRIUMPH-1: 25.0% average weight loss at 80 weeks on the highest dose vs 3.9% on placebo; Lilly plans to file in Q1 2027PMID 42814954 (opens in a new tab) · Lilly press release, Sept 29, 2026 (opens in a new tab)
  8. FDA advisory committee backs six peptides for the 503A list (law-firm summary; no rule)FDA meeting page (opens in a new tab) · Regulatory tracker
See the numbers
The numbers behind the tiles
FigureValueWhenSampleSource
US adults currently taking a GLP-112%Oct 27-Nov 2, 20251,350 adultsKFF, Nov 14, 2025 (opens in a new tab)
US adults who have ever taken a GLP-118%Oct 27-Nov 2, 20251,350 adultsKFF, Nov 14, 2025 (opens in a new tab)
US adults currently taking a GLP-16%Apr 23-May 1, 20241,479 adultsKFF, May 10, 2024 (opens in a new tab)
Tirzepatide net sales (Mounjaro $22,965M + Zepbound $13,542M)$36.5B2025Company filingLilly 10-K FY2025 (opens in a new tab)
Tirzepatide net sales (Mounjaro)$0.48B2022Company filingLilly 10-K FY2023 (opens in a new tab)
US adults using a GLP-1 for weight loss11%May 28-Jun 5, 20265,065 adultsGallup, Jul 7, 2026 (updated Sep 8) (opens in a new tab)
Weight-loss GLP-1 users on a compounded or custom-mixed version18%May 28-Jun 5, 20265,065 adultsGallup, Jul 7, 2026 (updated Sep 8) (opens in a new tab)

KFF counts any GLP-1 use (diabetes, weight loss or other); Gallup counts weight-loss use only, so the two are never drawn as one line.

Sources: KFF Health Tracking Polls (Nov 2025 (opens in a new tab), May 2024 (opens in a new tab)), Gallup 2026 (opens in a new tab), SEC EDGAR (Lilly 10-K FY2025 (opens in a new tab) and FY2023 (opens in a new tab)), openFDA Drugs@FDA, FDA shortage orders, PubMed and this site’s change log.

Which peptides are FDA-approved?

This site counts 35 FDA-approved entries, from Drugs@FDA and Purple Book records retrieved Oct 10, 2026. Of these, 6 are long enough that FDA licenses them as biologics, tesamorelin among them. The full list, with what each one treats, sits on the 35 FDA-approved peptides page. A few examples by first approval year:

Which peptides are FDA-approved?
EraExamplesWhat they treat
1970s and 1980sDesmopressin (1978), oxytocin (1980 or earlier), leuprolide (1985), octreotide (1988)Diabetes insipidus, labor induction, prostate cancer, acromegaly
2010sLiraglutide (2010), tesamorelin (2010), semaglutide (2017), PT-141 (2019)Type 2 diabetes and weight, HIV-related belly fat, low sexual desire in women
2020sTirzepatide (2022), SS-31 (elamipretide) (2025)Type 2 diabetes and weight, Barth syndrome
WithdrawnSermorelin, nesiritide, enfuvirtide, each pulled at its maker's requestGrowth hormone deficiency in children, heart failure, HIV

Sources: first approval years from this site's FDA snapshot (Drugs@FDA and the Purple Book, retrieved Oct 10, 2026). FDA withdrew those 3 approvals at the makers' request.

Another 16 entries here are approved only outside the US, and 13 of them are peptides. Examples include Semax and Selank in Russia and thymosin alpha 1 in China.

What are research peptides?

Research peptides are sold as research chemicals, labeled for research use only, and are not approved for use in people. Most of the peptide boom happens outside the pharmacy. The Peptide Evidence Gap study counted 1,307,440 US Google searches a month for the 104 entries here without a US approval. BPC-157 alone draws 301,000, GHK-Cu 201,000 and MOTS-c 60,500.

People use them for healing, growth hormone, focus, skin and longevity goals. Community reports describe faster tendon recovery on BPC-157 and TB-500, deeper sleep and smoother skin. There are more than 100 on this site alone, and 45 of the 104 have no published human study yet.

FDA has named research-labeled retatrutide among products of unknown quality sold for human use (FDA (opens in a new tab)).

The rules are moving toward access. Category 2 is FDA's list of bulk substances that "may present significant safety risks" in compounding (FDA (opens in a new tab)). BPC-157 was placed on it in 2023. On Apr 15, 2026, nominators withdrew 12 peptides, effective Apr 22. BPC-157, TB-500, injectable GHK-Cu, MOTS-c, KPV and Semax were among them. Leaving the list doesn't by itself make a peptide legal to compound (Category 2 explainer).

In July 2026, an FDA advisory committee backed six for the 503A compounding list: BPC-157, TB-500, KPV, MOTS-c, Semax and epitalon. That account comes from a law-firm summary; FDA has posted no minutes and made no rule yet. The regulatory tracker follows the next step.

How many peptides here are FDA-approved, and how many are not?

35 of the 150 peptides here are FDA-approved in the US; 104 have no US approval, and 45 of those have no published human study.

See the numbers
The 150 peptides on this site in four groups
GroupCountWhat it means
FDA-approved in the US35FDA has approved a drug made from it, and the approval stands. Some longer ones, such as tesamorelin, are licensed as biologics (BLAs).
No US approval, tested in people59Published human research, from small studies to phase 3 trials or an approval abroad.
No US approval, no human studies found45No finished or published study in people. The research is in animals, cells or test tubes.
Other11Withdrawn approvals, blends, an alias entry and approved drugs that are not peptides.
The 104 with no US approval, by furthest human evidence
TierCountWhat it meansExample
Approved outside the US16A regulator outside the US has approved a medicine made from it.Semax
Phase 3 trial10A phase 3 trial in people has finished, or its results are published.Retatrutide
Phase 2 trial14The furthest finished or published human research is a phase 2 trial.BPC-157
Phase 1 trial6The furthest finished or published human research is a phase 1 safety trial.GHRP-6
Small human studies only13People have taken it in published studies, but none is a finished phase 1 to 3 trial. These are pilots, case reports or small unphased studies.GHK-Cu
No human studies found45No finished or published study in people was found. The research is in animals, cells or test tubes.TB-500

The full list of 35: FDA-approved peptides.

FDA approvals from this site’s FDA-approved peptides list (each sourced to a saved FDA record); human evidence from the Peptide Evidence Gap study.

What are the most popular peptides, and do they work?

Studies and community reports often agree. Nausea leads the side effects of GLP-1 drugs in the STEP 1 trial (PMID 33567185) and in 410,198 Reddit posts (Sehgal, Nature Health 2026 (opens in a new tab)). MK-677, a growth hormone secretagogue that isn't a peptide, raised appetite and caused mild swelling in its 2-year trial (PMID 18981485). Those are the community's top complaints, too.

Where the two sides differ, product quality is one likely reason (PMID 42873503). Three retatrutide products tested in Australia held about half to almost double their labeled amount (PMID 42559975).

GLP-1 drugs. Semaglutide cut weight by 14.9% at 68 weeks in STEP 1 (PMID 33567185). Community reports describe "food noise" going quiet. Tirzepatide reached up to 20.9% at 72 weeks on the highest dose in SURMOUNT-1 (PMID 35658024). Community reports describe appetite control many find fuller than on semaglutide. Retatrutide reached 25.0% at 80 weeks on the highest dose in TRIUMPH-1, a trial of 2,339 adults (PMID 42814954). It isn't approved anywhere yet, and Lilly says it plans to file with FDA in Q1 2027. The tirzepatide vs retatrutide page compares the two.

Healing peptides. BPC-157 is the go-to in community reports for tendon, joint and gut problems, often with relief within weeks. The human record is thin. A 2025 review found 35 preclinical studies and 1 small human study (PMID 40756949). FDA's 2026 briefing counted five small human studies, about 80 people in all (FDA (opens in a new tab)).

Community reports rank TB-500 among the most trusted healing peptides, though it has no human study of its own. Its parent molecule, thymosin beta-4, is a different product. Injected, it reached phase 1 safety trials (PMID 20536472, PMID 34346165) and phase 2 heart studies; as eye drops it reached phase 3. Users often pair the two as the Wolverine Stack, and BPC-157 vs TB-500 splits their roles.

Skin, growth hormone and metabolism. GHK-Cu has small topical skin studies in people and no human study of injections. Community reports describe smoother skin by weeks 4 to 6. CJC-1295 + ipamorelin has no trial of the blend. CJC-1295 with DAC raised growth hormone in a phase 1 study (PMID 16352683), and ipamorelin's phase 2 gut-recovery trials led to no approval (PMID 25331030). In community reports it's the "clean" GH stack, with deeper sleep within 1 to 2 weeks (CJC-1295 vs ipamorelin).

In community reports MOTS-c is a subtle background peptide: more morning energy and endurance, though some notice nothing. No study has given it to people yet (Evidence Gap study). The most popular peptides page ranks the rest.

Semaglutide

FDA-approved

What studies show

Research Strong

STEP 1: 14.9% average weight loss at 68 weeks vs 2.4% on placebo; nausea and diarrhea were the most common side effects (PMID 33567185 (opens in a new tab)).

What community reports say

Community Strong

Community reports: "food noise" going quiet is the most described effect. Nausea during dose steps, constipation and regain after stopping are the top complaints.

Effects, community reports

  • Reported benefit: Food noise goes quiet
  • Common complaint: Nausea during dose steps

Tirzepatide

FDA-approved

What studies show

Research Strong

SURMOUNT-1: up to 20.9% average weight loss at 72 weeks on the highest dose vs 3.1% on placebo (PMID 35658024 (opens in a new tab)).

What community reports say

Community Strong

Community reports: the strongest enthusiasm of any GLP-1, with appetite control many find fuller than on semaglutide. Nausea, hair thinning months in, and cost are the common complaints.

Effects, community reports

  • Reported benefit: Strong appetite control
  • Common complaint: Hair thinning months in

Retatrutide

Phase 3

What studies show

Research Strong

TRIUMPH-1: 25.0% average weight loss at 80 weeks on the highest dose vs 3.9% on placebo, in 2,339 adults (PMID 42814954 (opens in a new tab)).

What community reports say

Community Moderate

Community reports: fast, strong appetite loss and renewed loss after a plateau; a faster resting heart rate is a common complaint. A 2026 study found 13,589 Reddit users reporting use before any approval (PMID 42873503 (opens in a new tab)).

Effects, community reports

  • Reported benefit: Renewed loss after a plateau
  • Common complaint: Faster heart rate

BPC-157

Phase 2

What studies show

Research Moderate(mostly animal studies)

A 2025 review found 36 studies: 35 preclinical (animal and cell) and 1 small human study, and no clinical safety data (PMID 40756949 (opens in a new tab)). Its furthest human research is an early-2000s phase 2 trial in ulcerative colitis, published only as a conference abstract, with no significant gap vs placebo (Evidence Gap study).

What community reports say

Community Strong

Community reports: the go-to for tendon, joint and gut problems, often with relief within weeks. Anxiety, palpitations and "no effect" blamed on the vial are the top complaints.

Effects, community reports

  • Reported benefit: Tendon and joint relief
  • Common complaint: Anxiety or palpitations

Where it stands: Not FDA-approved. Left Category 2 in April 2026; an advisory committee backed it in July 2026 (no rule yet). Banned in sport (WADA S0).

BPC-157 profileBPC-157 vs TB-500

TB-500

No human studies

What studies show

Research Moderate(animal and cell studies)

No human study of the TB-500 fragment. Its parent molecule, thymosin beta-4, is a different product: it reached phase 3 as eye drops, and injected thymosin beta-4 reached phase 1 safety trials (PMID 20536472 (opens in a new tab), PMID 34346165 (opens in a new tab)) and phase 2 heart studies (Evidence Gap study).

What community reports say

Community Strong

Community reports: one of the most trusted healing peptides, used for tendon, ligament and muscle injuries. Cost, product quality and early tiredness are the main complaints.

Effects, community reports

  • Reported benefit: Tendon and muscle recovery
  • Common complaint: Early tiredness

GHK-Cu

Small human studies

What studies show

Research Moderate

Human data come from small topical skin studies; no human study has tested injections (FDA review (opens in a new tab) cites limited human data).

What community reports say

Community Strong

Community reports: smoother skin texture by weeks 4 to 6 is the most repeated result. Stinging at the injection site and mcg vs mg math errors are common beginner problems.

Effects, community reports

  • Reported benefit: Smoother skin by weeks 4 to 6
  • Common complaint: Injection-site stinging

CJC-1295 + Ipamorelin

No trial of the blend

What studies show

Research Weak

No trial has tested the blend. CJC-1295 with DAC raised growth hormone in a phase 1 study (PMID 16352683 (opens in a new tab)); ipamorelin's phase 2 gut-recovery trials led to no approval (PMID 25331030 (opens in a new tab)).

What community reports say

Community Strong

Community reports: called the "clean" GH stack, with deeper sleep within 1 to 2 weeks and slow body recomposition over months. Water retention, tingling and mislabeled DAC products are the usual complaints.

Effects, community reports

  • Reported benefit: Deeper sleep in 1 to 2 weeks
  • Common complaint: Water retention

MOTS-c

No human studies

What studies show

Research Moderate(animal and cell studies)

No study has given MOTS-c to people yet; the research is in animals and cells (Evidence Gap study).

What community reports say

Community Moderate

Community reports: a subtle "background" metabolic peptide. More morning energy and endurance are the common reports; some users notice nothing.

Effects, community reports

  • Reported benefit: More morning energy
  • Common complaint: Some notice nothing

Where it stands: Not FDA-approved. Left Category 2 in April 2026; advisory committee backed it 7-5-2 in July 2026 (law-firm summary; no rule yet).

MOTS-c profileMetabolic peptides

See the numbers
The eight peptides side by side
PeptideStageResearchCommunityStudies vs usersKey source
SemaglutideFDA-approvedStrongStrongStudies and users agreeSTEP 1 (PMID 33567185 (opens in a new tab))
TirzepatideFDA-approvedStrongStrongStudies and users agreeSURMOUNT-1 (PMID 35658024 (opens in a new tab))
RetatrutidePhase 3StrongModerateStudies and users agreeTRIUMPH-1 (PMID 42814954 (opens in a new tab))
BPC-157Phase 2Moderate (mostly animal studies)StrongStudies and users partly agreeVasireddi 2025 review (PMID 40756949 (opens in a new tab))
TB-500No human studiesModerate (animal and cell studies)StrongStudies and users partly agreeEvidence Gap study; PMID 20536472 (opens in a new tab), PMID 34346165 (opens in a new tab)
GHK-CuSmall human studiesModerateStrongStudies and users partly agreeFDA Category 2 safety review
CJC-1295 + IpamorelinNo trial of the blendWeakStrongStudies and users partly agreePMID 16352683 (opens in a new tab), PMID 25331030 (opens in a new tab)
MOTS-cNo human studiesModerate (animal and cell studies)ModerateStudies and users partly agreeEvidence Gap study
Research and community levels are this site's ratings on each profile; studies cited inline.

How are peptides taken: injection, pills or nasal spray?

Most peptides are taken by injection. Of the 150 entries on this site, 116 list at least one injected route, and 90 list subcutaneous first. The other 34 are never injected: 25 are taken by mouth, 6 on the skin and 3 as a nasal spray. Of those 25 oral-only entries, 8 aren't peptides, such as MK-677 and orforglipron.

Swallowed peptides are mostly broken down before they reach the blood. Semaglutide tablets show the scale of the problem. They contain SNAC, an additive that aids absorption, and still only about 0.4% to 2% reaches the bloodstream (Rybelsus label (opens in a new tab)).

A few still work by mouth or nose. Semaglutide comes as an injection and as tablets: Rybelsus (2019), Ozempic tablets and the Wegovy pill (December 2025). Linaclotide is an oral peptide that acts inside the gut, so it doesn't need to reach the blood. Desmopressin comes as tablets and a nasal spray, and glucagon has a nasal form.

Semax and Selank are registered in Russia as nasal drops. GHK-Cu is topical in skin studies; no human study has tested it as an injection. Oral BPC-157 is a common question. Its oral bioavailability has never been measured in people, but rat studies support an oral route for gut use (PMID 24304574).

Injecting for the first time? Read how to inject peptides, how to reconstitute peptides and insulin syringe units explained. The peptide calculator turns your vial and dose into syringe units.

How are peptides taken?

116 of the 150 peptides here are injected; 25 are taken only by mouth, 6 only on the skin and 3 only as a nasal spray.

  • Injected 116
  • By mouth only 25
  • Skin only 6
  • Nasal spray only 3
See the numbers
Routes listed on the 150 peptide profiles
RouteNever injectedListing it at allExamples
Subcutaneous (under the skin)–104SemaglutideTirzepatideBPC-157TB-500
Intramuscular–25
Intravenous–28
Other injection (intrathecal, intra-arterial, intraperitoneal, intracerebroventricular)–4
Oral or sublingual2530LinaclotideMK-677
Nasal313SemaxSelankDesmopressin
Topical (skin)69ArgirelineMatrixylGHK-Cu

Injected in any way: 116. A profile can list several routes, so the "listing it at all" column adds up to more than 150.

Counts from the administration route on every peptide profile on this site.

Are peptides safe? What side effects do people report?

For approved GLP-1 drugs, the benefits are well measured. Adults in STEP 1 and SURMOUNT-1 lost 14.9% and up to 20.9% of body weight on average. Placebo groups lost 2.4% and 3.1% (PMID 33567185, PMID 35658024). Approved GLP-1 drugs have trial data on thousands of people and labels that list their side effects.

The risks differ by peptide and by product. A pharmacy drug and a research vial with the same name carry different risks. The table sums up what's known; the full safety guide goes peptide by peptide.

Are peptides safe? What side effects do people report?
RiskWhat is knownSource
Stomach effects on GLP-1sNausea and diarrhea were the most common side effects in STEP 1. In a Reddit study, 43.5% of 67,008 users described at least one side effect, nausea firstSTEP 1 (PMID 33567185); Sehgal, Nature Health 2026 (opens in a new tab)
Product quality41.6% to 71.1% of 6,441 gray-market samples failed quality criteria, and 15% had endotoxin. Three retatrutide products held about half to almost double their labeled amountMendias and Awan, 2026 preprint (opens in a new tab); PMID 42559975
Math and mixing errorsFDA has reported dosing errors with compounded GLP-1 vials. Community reports name mcg vs mg mix-ups, a 1,000x error, as a common beginner mistakeFDA (opens in a new tab); community reports
Little long-term human data"No clinical safety data were found" for BPC-157. Here, 45 of 104 unapproved entries have no human studyPMID 40756949; Evidence Gap study
Heart and metabolic signalsMK-677's hip-fracture trial stopped early over a heart-failure signal, and fasting glucose rose in its 2-year trial. A faster heart rate is among the top retatrutide reports on RedditPMID 21067829; PMID 18981485; PMID 42873503
Pregnancy and cancer historyThe Wegovy label warns of fetal harm. Tesamorelin is contraindicated in pregnancy and active cancer. Semaglutide and tirzepatide labels carry a boxed warning for thyroid C-cell tumors in rodents and rule out people with a personal or family history of medullary thyroid cancer or MEN 2Wegovy label (opens in a new tab); Egrifta WR and Zepbound labels

Sources: each row's source sits in its last column; every PMID is listed under References. The dosing mistakes guide covers the math, how to verify a COA covers product checks, and the interaction checker flags known drug pairs.

Are peptides legal?

It depends on the product's status. In the US, one molecule can be a prescription drug, a compounded copy or a research chemical, and each has its own rules. Rules outside the US differ by country.

Are peptides legal?
StatusWhat it meansExamples
FDA-approvedPrescription onlySemaglutide, tirzepatide, PT-141
CompoundedNeeds a prescription. Pharmacies compound from approved drugs or allowed bulk substances. Copies that are essentially the approved drug had to stop after grace periods ending Feb to May 2025. FDA declared the shortages over for tirzepatide on Oct 2, 2024 (re-affirmed Dec 19, 2024) and semaglutide on Feb 21, 2025Semaglutide and tirzepatide copies, 2022 to 2025
Research use onlySold as research chemicals, not approved for people. FDA warning letters target sellers whose sites show human useRetatrutide, BPC-157
Approved abroadApproved in another country, not in the USSemax and Selank (Russia)
Banned in sportProhibited for tested athletes, in and out of competitionBPC-157 (WADA S0); ipamorelin and MK-677 (WADA S2)

Sources: FDA shortage orders for semaglutide (opens in a new tab) and tirzepatide (opens in a new tab), FDA's GLP-1 concerns page (opens in a new tab), the WADA 2026 Prohibited List (opens in a new tab) and each peptide's legal section here.

The regulatory tracker logs every status change with its date, and the FDA-approved list shows what's approved now. The Category 2 explainer covers the 2026 compounding changes.

How do you weigh peptide studies against community reports?

Start with the evidence ladder. From strongest to weakest, it runs FDA approval, phase 3 trials, phase 1 and 2 trials, small human studies, then animal or cell studies. The Peptide Evidence Gap study places every unapproved peptide here on that ladder.

Community reports add what trials can't. They show scale: 13,589 Reddit users reported taking retatrutide before any approval (PMID 42873503). They catch early signals, too. GLP-1 users described menstrual and temperature changes that labels don't capture well, and the study authors flag them for clinical study (Sehgal, Nature Health 2026 (opens in a new tab)). And they often match the trials, as MK-677's appetite and swelling reports do (PMID 18981485).

How do you weigh peptide studies against community reports?
SourceWhat it addsScale
Reddit and forumsLogs of effects, side effects and timing410,198 GLP-1 posts and 148,640 retatrutide posts and comments studied by researchers
YouTube explainers and interviewsReach, and the questions people actually askThe top peptide explainer passed 19 million views
Peptide profiles on this siteCommunity confidence, reported benefits and complaints, labeled beside the studies150 peptides

Sources: Sehgal, Nature Health 2026 (opens in a new tab) and Sehgal, JAMA Network Open 2026 (PMID 42873503); YouTube view counts read Oct 31, 2026.

Community reports have limits: there's no control group, posters choose themselves, and a vial may not match its label (PMID 42559975). The JAMA Network Open authors call their own findings hypothesis-generating.

Across 150 peptides on this site, studies and community reports agree on 37 and partly agree on 68. They point different ways on 6, and 39 have too few user reports to compare.

That side-by-side view is why Peptide Schedule exists. Every profile puts studies and community reports next to each other, with each claim labeled as study data or community reports. The regulatory tracker logs FDA and compounding changes, and the change log keeps a dated record of FDA status, safety and dosing changes. There are 86 dosage calculators, a protocol planner with dose tracking, and an editorial policy that ranks sources. More on the about page.

How often do studies and community reports agree?

Across 150 peptides, the two agree on 37 and partly agree on 68; they point different ways on 6.

See the numbers
How studies and community reports line up, 150 peptides
LabelCount% of 150What it meansExample
Agree3725%Study results and community reports point the same way.Semaglutide
Partly agree6845%They match on some effects or risks and differ on others.BPC-157
Few user reports3926%Studies exist, but too few community reports to compare.Mazdutide
Disagree64%Community reports and studies point different ways.Dihexa
Each peptide profile on this site rates its studies and its community reports separately, then says how the two line up.

Where should a beginner start with peptides?

Start with the facts on one peptide, then use the tools. Each step below opens a free page on this site, and none of them picks a peptide for you.

Where should a beginner start with peptides?
StepWhere on the site
Read the profile: studies, community reports, safety gradePeptide directory
Check FDA status and recent changesFDA-approved list, regulatory tracker
Compare optionsSemaglutide vs tirzepatide, BPC-157 vs TB-500
Check interactionsInteraction checker
Do the vial math before any drawPeptide calculator
Plan and logProtocol planner

Sources: this site's own tools and data, each linked in its row.

Have a goal in mind? The best peptides for weight loss, best peptides for healing and best peptides for muscle growth guides weigh each option's evidence. The peptide supplies guide lists what an injection needs.

Experienced users pass on the same advice to beginners, per community reports. Change one thing at a time, so you can tell what worked. Give growth-hormone peptides months, not weeks. And treat product quality as the first variable before you blame the peptide.

Frequently Asked Questions

Yes, Ozempic is semaglutide, a GLP-1 receptor agonist peptide that FDA approved for type 2 diabetes in 2017. The same molecule is sold as Wegovy for weight management. In the STEP 1 trial, adults on semaglutide lost 14.9% of their body weight at 68 weeks, against 2.4% on placebo (PMID 33567185).

No, peptides are short chains of amino acids, and most act on receptors on the surface of cells. Anabolic steroids are small molecules built on the steroid ring that cholesterol also has. SARMs are small molecules too. Sport bans cross both groups: WADA prohibits BPC-157, MK-677 and growth hormone secretagogues such as ipamorelin.

For FDA-approved peptides, yes: semaglutide, tirzepatide and PT-141 are prescription drugs, and a compounded version also needs a prescription. Products labeled "for research use only" aren't approved for people at all. FDA has sent warning letters to sellers whose websites show these products being used by people.

It depends on the peptide. Approved GLP-1 drugs often cause nausea and diarrhea (STEP 1, PMID 33567185). Research peptides add two risks: little human safety data and uneven products. In one test set, 41.6% to 71.1% of 6,441 gray-market samples failed basic quality criteria (Mendias and Awan, 2026 preprint).

No peptide is risk-free, and the right answer depends on your health. FDA-approved peptides have the best-known safety records, because large trials and drug labels track their side effects. Semaglutide and tirzepatide were tested in trials of 1,961 and 2,539 adults (PMID 33567185, PMID 35658024). Every profile on this site shows a safety grade from A to D.